from Australia to Europe, some participants who indicated that they worked with the Rhinolopus spp. may likely have worked with species found outside of Asia. Involvement with bats most often consisted of capturing or handling them in the fi eld (90%), followed by capturing or handling them in the laboratory (36%). Urine and feces were encountered most frequently ("always" or "most of the time" by 66%-68% of participants); contact with blood, saliva, or tissues and bites or scratches reportedly occurred less often ("always" or "most of the time" by 4%-28% of participants).
The serum samples from all 90 participants were negative for antibodies against inactivated SARSCoV, and samples from all but 1 were negative for SARS-CoV N protein. The 1 positive sample gave a strong signal (optical density 1.08 at 405 nm at a 1:400 dilution) by SARS-CoV N protein EIA and against SARS-CoV N by Western blot but gave no reactivity against recombinant SARSCoV spike protein or inactivated SARS-CoV by either EIA or Western blot. Because the N protein has a region that is relatively conserved among all known coronaviruses (7), the antibodies against SARS-CoV N protein could have been induced by other CoVs. Previous studies have demonstrated that SARS-CoV N protein can cross-react with polyclonal antiserum induced by group 1 animal CoVs (8) .
To address the possibility that the antibodies from this serum sample were not specifi c to SARS-CoV, we tested it against recombinant N proteins of human CoVs, HCoV-229E, HCoV-OC43, NL63, and HKU-1. The serum reacted to all 4 N proteins, by EIA and Western blot, at titers of 400-1,600. We then tested the sample against 3 recombinant fragments of the N protein from each of 3 viruses: SARSCoV, HCoV-229E, and HCoV-OC43. One of these fragments, N2, contains a highly conserved motif (FYYLGTGP) that should detect cross-reacting antibodies; the other 2 fragments should detect antibodies specifi c to the strain or group. The serum reacted to 2 of 3 fragments from HCoV-OC43 and -229E but to only the N2 fragment with the conserved motif from SARSCoV (Figure) , which suggests that the antibodies against SARS-CoV N were likely induced by a CoV that was not SARS-like.
If the antibodies were induced by a SARS-like CoV infection, we would expect to have also detected antibodies against recombinant S protein (9) or recombinant fragments representing antigenically distinct regions of the N protein of SARS-CoV. We did not detect either; instead, we detected antibodies against the antigenically distinct N fragments from group 1 and 2 human CoVs. Thus, this survey of a sample of bat biologists, who were exposed primarily to North American bats but also to bats from Asia and Africa, showed no evidence of SARSlike CoV infection.
Our survey found no evidence of SARS-CoV transmission from bats to humans. However, since the conclusion of this study, Dominguez et al. found coronavirus RNA in bats in North America, particularly Eptesicus fuscus and Myotis occultus (10), 2 species of the genera handled by 25% of the participants in our survey. Of interest is whether the bat biologists who worked with these bats might be at risk for infection with group 1 bat CoVs. Unfortunately, the high likelihood of infection with human group 1 CoVs will make it diffi cult to address this question. . This conserved motif is found in HCoV-OC43 N2, HCoV-229E N2, and SARSCoV N2 recombinant protein fragments. The sizes of the expressed protein fragments used in this study were confi rmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. In addition, the reactivity of each protein fragment was confi rmed by using Western blot with the anti-His antibody and the respective convalescent-phase serum. The mean optical density (OD) of absorbance at 405 nm (490-nm reference) of duplicate wells is shown. Error bars represent the standard deviation of duplicate wells.
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